Rockville, MD, United States of America

Shigui Zhu

USPTO Granted Patents = 3 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Shigui Zhu: Innovator in Chimeric Antigen Receptors

Introduction

Shigui Zhu is a prominent inventor based in Rockville, MD (US), known for his significant contributions to the field of immunotherapy. He holds a total of 3 patents that focus on innovative approaches to treating autoimmune disorders and cancer through advanced chimeric antigen receptor (CAR) technologies.

Latest Patents

One of his latest patents is titled "Bispecific chimeric antigen receptors targeting CD20 and BCMA." This invention provides a bispecific chimeric antigen receptor that includes an scFv targeting CD20 and another targeting BCMA. The design incorporates a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. This CAR technology is aimed at treating autoimmune disorders or cancer effectively.

Another notable patent is "Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof." This invention presents a combined chimeric antigen receptor that targets both CD19 and CD20. It consists of an scFv targeting these antigens, along with a hinge region, a transmembrane region, and an intracellular signaling domain. The patent also includes a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector. The experimental results indicate that this chimeric antigen receptor demonstrates exceptional killing ability against tumor cells, making it a promising option for treating CD19 and/or CD20 positive B-cell lymphoma, leukemia, and other related diseases.

Career Highlights

Shigui Zhu is currently associated with Abelzeta Inc., where he continues to advance his research and development in the field of CAR technologies. His work has been instrumental in pushing the boundaries of immunotherapy, providing new avenues for treatment.

Collaborations

He collaborates with notable colleagues such as Yihong Yao and Jiaqi Huang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Shigui Zhu's work in developing chimeric antigen receptors represents a significant advancement in the treatment of cancer and autoimmune disorders. His innovative patents and collaborations highlight his commitment to improving therapeutic options in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…